share_log

Jaguar Health (NASDAQ:JAGX) Receives New Coverage From Analysts at StockNews.com

Jaguar Health (NASDAQ:JAGX) Receives New Coverage From Analysts at StockNews.com

捷豹健康（纳斯达克股票代码：JAGX）获得StockNews.com分析师的新报道
Defense World ·  2022/09/25 02:11

Equities researchers at StockNews.com began coverage on shares of Jaguar Health (NASDAQ:JAGX – Get Rating) in a research report issued on Sunday. The firm set a "hold" rating on the biotechnology company's stock.

StockNews.com的股票研究人员开始报道以下股票 捷豹健康（纳斯达克股票代码：JAGX — 获取评级） 在周日发布的研究报告中。该公司对这家生物技术公司的股票设定了 “持有” 评级。

Jaguar Health Stock Performance

捷豹健康股票表现

Shares of Jaguar Health stock opened at $0.17 on Friday. Jaguar Health has a 12-month low of $0.15 and a 12-month high of $2.66. The company has a market cap of $20.00 million, a price-to-earnings ratio of -0.15 and a beta of 1.65. The company has a current ratio of 1.02, a quick ratio of 0.73 and a debt-to-equity ratio of 8.47. The company's 50-day moving average price is $0.25 and its 200-day moving average price is $0.37.

周五，捷豹健康股票开盘价为0.17美元。捷豹健康创下12个月低点0.15美元，12个月高点2.66美元。该公司的市值为2,000万美元，市盈率为-0.15，beta值为1.65。该公司的流动比率为1.02，速动比率为0.73，债务与权益比率为8.47。该公司的50天移动平均线价格为0.25美元，其200天移动平均线价格为0.37美元。

Get
获取
Jaguar Health
捷豹健康
alerts:
警报：

Jaguar Health (NASDAQ:JAGX – Get Rating) last announced its quarterly earnings results on Monday, August 22nd. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.10. Jaguar Health had a negative net margin of 652.35% and a negative return on equity of 486.62%. The firm had revenue of $2.92 million for the quarter. On average, equities analysts expect that Jaguar Health will post -0.67 earnings per share for the current fiscal year.

捷豹健康（纳斯达克股票代码：JAGX — Get Rating）上次公布季度财报是在8月22日星期一。这家生物技术公司公布了本季度每股收益（EPS）（0.12美元），比分析师的共识预期（0.22美元）高出0.10美元。Jaguar Health的净利润率为负652.35％，负股本回报率为486.62％。该公司本季度的收入为292万美元。股票分析师平均预计，Jaguar Health将在本财年公布每股收益为-0.67。

Institutional Inflows and Outflows

机构流入和流出

Institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC bought a new position in shares of Jaguar Health in the first quarter worth approximately $1,079,000. Virtu Financial LLC increased its position in shares of Jaguar Health by 76.1% in the first quarter. Virtu Financial LLC now owns 229,270 shares of the biotechnology company's stock worth $162,000 after purchasing an additional 99,073 shares during the last quarter. Millennium Management LLC increased its position in shares of Jaguar Health by 152.3% in the second quarter. Millennium Management LLC now owns 533,153 shares of the biotechnology company's stock worth $157,000 after purchasing an additional 321,795 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Jaguar Health by 507.3% in the first quarter. Bank of New York Mellon Corp now owns 169,749 shares of the biotechnology company's stock worth $120,000 after purchasing an additional 141,796 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Jaguar Health by 153.3% in the first quarter. Goldman Sachs Group Inc. now owns 54,770 shares of the biotechnology company's stock worth $39,000 after purchasing an additional 33,148 shares during the last quarter. 7.40% of the stock is currently owned by institutional investors.
机构投资者最近修改了该股的持有量。Renaissance Technologies LLC在第一季度购买了Jaguar Health的新股票，价值约为10.79万美元。Virtu Financial LLC在第一季度将其在捷豹健康的股票头寸增加了76.1％。Virtu Financial LLC在上个季度又购买了99,073股股票后，现在拥有这家生物技术公司的229,270股股票，价值16.2万美元。Millennium Management LLC在第二季度将其在捷豹健康的股票头寸增加了152.3％。Millennium Management LLC在上个季度又购买了321,795股股票后，现在拥有这家生物技术公司的533,153股股票，价值15.7万美元。纽约银行梅隆公司在第一季度将其在捷豹健康股票中的头寸增加了507.3％。纽约银行梅隆公司在上个季度又购买了141,796股股票后，现在拥有这家生物技术公司的169,749股股票，价值12万美元。最后，高盛集团公司在第一季度将其在捷豹健康的股票头寸增加了153.3％。高盛集团公司在上个季度又购买了33,148股股票后，现在拥有这家生物技术公司的54,770股股票，价值39,000美元。该股票的7.40％目前由机构投资者持有。

Jaguar Health Company Profile

捷豹健康公司简介

(Get Rating)

（获取评分）

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Jaguar Health, Inc是一家商业阶段的制药公司，专注于为患有胃肠道不适，特别是慢性和使人衰弱的腹泻的人和动物开发处方药。该公司通过两个部门运营，即人类健康和动物健康。它推销Mytesi，用于缓解接受抗逆转录病毒疗法的成年艾滋病毒/艾滋病成年人的非传染性腹泻的症状。

See Also

另见

  • Get a free copy of the StockNews.com research report on Jaguar Health (JAGX)
  • Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
  • MarketBeat: Week in Review 9/19 – 9/23
  • Why Does Tesla Stock Remain Resilient?
  • 2 Semiconductor Stocks To Watch For Reversals
  • Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
  • 免费获取 StockNews.com 关于捷豹健康 (JAGX) 的研究报告的副本
  • 华尔街对Datadog的热情会带来巨大收益吗？
  • MarketBeat：本周回顾 9 月 19 日至 9 月 23 日
  • 为什么特斯拉股票保持弹性？
  • 2 只值得关注的半导体股有望逆转
  • 好市多的盈利后价格疲软是买入的好时机吗？

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.

接收《捷豹健康日报》的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收捷豹健康及相关公司最新新闻和分析师评级的简明每日摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发